Second-line treatment of metastatic gastric cancer: Current options and future directions
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second-line treatment of metastatic gastric cancer: Current options and future directions
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 21, Issue 41, Pages 11621
Publisher
Baishideng Publishing Group Inc.
Online
2015-11-02
DOI
10.3748/wjg.v21.i41.11621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LBA15A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER
- (2017) K. Muro et al. ANNALS OF ONCOLOGY
- Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial
- (2015) Kazuhiro Nishikawa et al. EUROPEAN JOURNAL OF CANCER
- Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
- (2014) D S Zhang et al. BRITISH JOURNAL OF CANCER
- Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study
- (2014) Yulong Zheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
- (2014) Yasutsuna Sasaki et al. CANCER SCIENCE
- Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
- (2014) Katsuhiko Higuchi et al. EUROPEAN JOURNAL OF CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study
- (2014) Manuel Barreto Miranda et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
- (2014) Rosine Guimbaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
- (2014) Susan J Dutton et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
- (2014) Roberto Iacovelli et al. PLoS One
- Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
- (2013) H. S. Kim et al. ANNALS OF ONCOLOGY
- Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
- (2013) N C Tebbutt et al. BRITISH JOURNAL OF CANCER
- ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
- (2013) Sara De Dosso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702)
- (2013) Yoshinari Mochizuki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study
- (2013) M. Martin-Richard et al. INVESTIGATIONAL NEW DRUGS
- Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
- (2013) Wasaburo Koizumi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma
- (2013) Lin Shen et al. Journal of Cancer Research and Therapeutics
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
- (2013) Shuichi Hironaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients
- (2013) Yan-Ying Shen WORLD JOURNAL OF GASTROENTEROLOGY
- Optimal indications for second-line chemotherapy in advanced gastric cancer
- (2012) Hiroko Hasegawa et al. ANTI-CANCER DRUGS
- A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
- (2012) Sun Jin Sym et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer
- (2012) K.R. Schønnemann et al. EUROPEAN JOURNAL OF CANCER
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Expression and Amplification in Patients with Localized Gastric Cancer
- (2011) Y. Y. Janjigian et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)
- (2011) Tetsuya Hamaguchi et al. Gastric Cancer
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
- (2010) D. Kanagavel et al. ANNALS OF ONCOLOGY
- The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression
- (2010) Yanwei Ye et al. ANNALS OF SURGICAL ONCOLOGY
- Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer
- (2010) Haijun Zhong et al. ANTI-CANCER DRUGS
- Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer
- (2010) Daisuke Takahari et al. Gastric Cancer
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens
- (2009) N. Baize et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Irinotecan Plus Capecitabine as a Second-line Treatment after Failure of 5-Fluorouracil and Platinum in Patients with Advanced Gastric Cancer
- (2009) Q. Sun et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens
- (2009) Ramazan Yildiz et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
- (2008) V Catalano et al. BRITISH JOURNAL OF CANCER
- A Phase II Study of Sequential Methotrexate and 5-fluorouracil Chemotherapy in Previously Treated Gastric Cancer: A Report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 Trial
- (2008) T. Hamaguchi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Multi-Center Phase II Study for Combination Therapy with Paclitaxel/Doxifluridine to Treat Advanced/Recurrent Gastric Cancer Showing Resistance to S-1 (OGSG 0302)
- (2008) H. Takiuchi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer
- (2008) M.-D. Seo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer
- (2007) Bin Kang et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started